טוען...
Immune Checkpoint Inhibitor‐Associated Myocarditis
Immune checkpoint inhibitors (ICIs) are approved for a wide range of malignancies. They work by priming the immune system response to cancer and have changed the landscape of available cancer treatments. As anticipated, modulation of the regulatory controls in the immune system with ICIs results in...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156176/ https://ncbi.nlm.nih.gov/pubmed/29802219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0130 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|